Welcome to AZ MedX

AstraZeneca’s Respiratory & Immunology medical resource centre for healthcare professionals

Discover the latest advances and approaches in asthma, COPD and more

This site is intended for the use of Healthcare Professionals only. By clicking the link below you declare and confirm:

If you are not a Healthcare Professional, please follow this link for information on global patient resources.

AstraZeneca’s Early Science Ambition

Our bold ambition is to achieve disease modification and clinical remission in respiratory and immunology

 

We aim to transform the treatment of asthma and chronic obstructive pulmonary disease (COPD) by eliminating preventable asthma attacks across all severities and removing COPD as a leading cause of death through earlier, biology-led treatment [1]. In addition, we are also investigating other respiratory conditions with high unmet need, including idiopathic pulmonary fibrosis (IPF) and chronic cough.

  • Asthma icon
  • COPD icon
  • IPF icon
  • Cough icon

Our strategic respiratory research focus is divided into four mechanistic and complementary approaches in chronic lung disease:

  • lung immunity

    Immune Mechanisms

    Restoring a healthy balance in the immune system might be possible through
    immunomodulation, improved cell metabolism and by battling viruses and bacteria in the lungs.

  • lung regeneration

    Lung Damage

    Repairing lung damage by stimulating regrowth of lung cell tissue could restore lost lung function in obstructive lung diseases such as COPD and IPF.

  • lung epithelium

    Abnormal Cell Repair

    In many lung diseases the program regulating cell repair is altered. By understanding abnormal repair processes of cells lining the lung and how these lead to tissue remodeling, we aim to identify new drug targets that could change the course of chronic respiratory diseases.

  • neuronal functions

    Neuronal Dysfunction

    Cough is a neuronal reflex that is normally protective, but in idiopathic cough patients this reflex is triggered inappropriately and becomes troublesome, dramatically impacting quality of life.

Our toolbox

We have expanded our toolbox of drug modalities beyond the more traditional small molecules and monoclonal antibodies, to allow us to target any novel biology we uncover, and also to access targets in the body that were previously seen as hard to reach.

We investigate the best delivery routes for our drug modalities, whether that be systemic or inhaled treatments.

  • Anticalin proteins

    Anticalin® proteins

  • small molecules

    Small molecules

  • monoclonal antibodies

    Monoclonal antibodies

  • modified RNA

    Modified RNA

  • antisense oligonucleotides

    Antisense oligonucleotides

  • PROTACs

    PROTACs

  • peptides

    Peptides

  • oligonucleotide conjugate

    Oligonucleotide conjugate

  • CRISPR-Cas9

    CRISPR-Cas9

  • Fragment antibodies

    Fragment antibodies

References

References:

[1] Global Initiative for Chronic Obstructive Lung Disease. 2020. Available from: https://goldcopd.org

You are now leaving: http://azmedx.com/

By following this link you will be leaving the AZ MedX website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to AZ MedX